Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20024WP" target="_blank" >RIV/61988987:17110/19:A20024WP - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/19:10386115 RIV/00179906:_____/19:10386115 RIV/00843989:_____/19:E0108242
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pubmed/30522922" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/30522922</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S0140-6736(18)32984-2" target="_blank" >10.1016/S0140-6736(18)32984-2</a>

Result language
angličtina
Original language name
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Original language description
Background Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)